BACKGROUND AND PURPOSE: Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkappaB inhibitor reduces atherosclerosis. METHODS: Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-alpha and adiponectin were also measured. RESULTS: The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin. CONCLUSIONS: A new NFkappaB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.
BACKGROUND AND PURPOSE:Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkappaB inhibitor reduces atherosclerosis. METHODS:Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-alpha and adiponectin were also measured. RESULTS: The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin. CONCLUSIONS: A new NFkappaB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.
Authors: F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier Journal: Diabetologia Date: 2012-05-18 Impact factor: 10.122
Authors: T Shimo; Y Adachi; K Umezawa; M Okigaki; J Takaya; S Taniuchi; S Ikehara; K Kaneko Journal: Clin Exp Immunol Date: 2011-11 Impact factor: 4.330
Authors: Man C Wong; Janna A van Diepen; Lihui Hu; Bruno Guigas; Hetty C de Boer; Gijs H van Puijvelde; Johan Kuiper; Anton J van Zonneveld; Steven E Shoelson; Peter J Voshol; Johannes A Romijn; Louis M Havekes; Jouke T Tamsma; Patrick C N Rensen; Pieter S Hiemstra; Jimmy F P Berbée Journal: Atherosclerosis Date: 2011-07-12 Impact factor: 5.162
Authors: Anju Nohria; Scott Kinlay; J Stewart Buck; Whitney Redline; Robert Copeland-Halperin; Sora Kim; Joshua A Beckman Journal: J Am Heart Assoc Date: 2014-01-03 Impact factor: 5.501